Introduction {#s1}
============

The occurrence and timing of menarche and menopause play major roles in a woman\'s life and reproduction-related events. Menopause is the final reproductive event and unambiguously marks the ovarian aging and exhaustion of the primordial follicle pool in women [@pone.0058766-McGee1]. Menopause at a younger age often predicts an earlier induction of subfertility, sterility, and transition to cycle irregularity and vice versa [@pone.0058766-teVelde1].

Generally, age at natural menopause (ANM) ranges between 40--60 years with a median of 49 to 52 years, depending on the population [@pone.0058766-Morabia1]. Population-based studies report that the beginning of transition from regular to irregular menstrual cycles is 6--7 years ahead of ANM. This probably reflects the end of female fertility, which is nearly 10 years ahead of ANM [@pone.0058766-teVelde2]. Menopause age variation influences the levels of serum estrogen, follicle stimulating hormone, and progesterone, all which affect the well-being of women. Series studies report that the variation of menopause is associated with several major age-related diseases [@pone.0058766-Ossewaarde1], such as cardiovascular disease [@pone.0058766-Murabito1], [@pone.0058766-Kannel1], breast cancer [@pone.0058766-Monninkhof1], osteoporosis [@pone.0058766-Burger1], and depression [@pone.0058766-Cairney1]. So, identifying factors which determine variations of ANM may provide insights into the pathogenesis of these diseases.

ANM is a complex trait, influenced by multiple environmental and genetic factors [@pone.0058766-vanNoord1]. ANM has high heritability (70%). Genome-wide association studies (GWAS) have identified multiple genetic loci which influence ANM [@pone.0058766-He1]--[@pone.0058766-He2]. All of these GWAS were exclusively conducted in European-ancestry populations. Given the considerable differences in genetic architecture including allele frequencies, linkage disequilibrium (LD) structure and genetic diversity across ethnic groups, it is important to investigate whether GWAS-identified variants are associated with ANM in non-European populations. In this current study, we report a systematic evaluation of the GWAS-identified loci in association with ANM among Chinese.

Methods {#s2}
=======

Study Participants and Data Collection {#s2a}
--------------------------------------

This analysis included women from Shanghai, China, who were participants in multiple ongoing GWAS: the Shanghai Breast Cancer Genetics Study (SBCGS) [@pone.0058766-Long1], the Shanghai Endometrial Cancer Genetics Study (SECGS) [@pone.0058766-Delahanty1], the Shanghai Diabetes Genetics Study (SDGS) [@pone.0058766-Shu1], the Shanghai Colorectal Cancer Genetics Study [@pone.0058766-Jia1], the Upper GI Cancer Genetics Study, and the Panscan Cancer Genetics Study [@pone.0058766-Amundadottir1]. Among these studies, 4,106 reported detailed information of menopause. We excluded 573 women including 390 individuals whose menopause were disease-related, 158 individuals who took hormone replacement treatment, and 25 individuals with other non-nature cause menopause. Thus, 3,533 post-menopausal women were finally included in this study.

All parent studies are population-based and similar study protocols were used across studies to collect blood or buccal cell samples and relevant exposure information. Interviews were conducted in-person, and structured epidemiological questionnaires were administered by trained interviewers. Age at natural menopause (ANM) is defined as the age when menstrual periods ceased permanently and naturally (in years). Anthropometric characteristics including birth date, education, occupation, and age at menarche were collected in addition to information regarding individual habits, history of hormone replacement therapy, prior use of oral contraceptives, and post-disease status. Written, informed consent was obtained from all participants prior to interview, and study protocols were approved by the institutional review boards of all institutions involved in the study.

SNP Selection and Genotyping {#s2b}
----------------------------

To date, 28 SNPs have been reported to be associated with ANM in four GWASs with *P*\<5×10^−8^ among European-ancestry women [@pone.0058766-He1]--[@pone.0058766-Lunetta1]. These SNPs represent 19 independent loci with low pairwise linkage disequilibrium (LD) (r^2^\<0.2) based on the HapMap Asian data ([Table S1](#pone.0058766.s001){ref-type="supplementary-material"}). We also searched flanking 500kb of each of the 28 index SNPs using the HapMap data. There were three common SNPs (MAF\>0.01) which are in strong LD (r^2^≥0.8) with the index SNP in European-ancestry, but not in Asian-ancestry populations (r^2^\<0.2). Three such SNPs, rs4667673, rs2517388, and rs12294104, were also included in this study ([Table S1](#pone.0058766.s001){ref-type="supplementary-material"}).

Genotyping of all participants was performed using Affymetrix SNP Array 6.0 [@pone.0058766-Shu1], Illumina Omniexpress [@pone.0058766-Petersen1], Illumina 550 [@pone.0058766-Petersen1], Illumina 660. Detailed quality control (QC) procedures were described in these studies. In general, we removed SNPs with minor allele frequency (MAF) less than 5%, Hardy-Weinberg *P-*values \<1×10^−5^, samples with \>5% missing genotypes, inconsistent sex between self-reported and genotype based, non-Asian subjects based on clustering with HapMap subjects, and close-relationship subjects based on identity-by-descent (IBD) analyses.

For SNPs which were not directly genotyped through the GWAS chip, imputed data were extracted. Using the Han Chinese (CHB) and Japanese (JPT) data from HapMap Phase 2 (release 24) and Phase 3 (release 2) as the references, we used MACH 1.0 software (<http://www.sph.umich.edu/csg/abecasis/MaCH/>) to conduct imputation within each GWAS. The imputation quality RSQR was more than 0.91 for all SNPs included in the present study, with the exceptions of rs7246479 (0.79) and rs2277339 (0.77). Dosage data (with imputation uncertainty taken into account) were investigated in relation to ANM.

Statistical Analysis {#s2c}
--------------------

ANM was presented as the means ± SD between different groups. Student's t-test and analysis of variance (ANOVA) were applied to evaluate the differences of ANM by non-genetic factors. Linear regression was used to derive beta coefficients and 95% CIs for associations between genotypes and ANM under the additive model. All regression models include adjustment for birth cohort, education, and disease status. *P*-values reported for single SNPs are one-tailed since the hypothesis tested is whether the direction of association was consistent between Asian-ancestry and European-ancestry women. Program Quanto (<http://hydra.usc.edu/gxe/>) was used to estimate statistical power.

The binomial sign test was conducted to assess the consistency of the associations previously reported and seen in our study. Genetic risk scores (GRS) were used to summarize multiple SNPs [@pone.0058766-Ehret1], [@pone.0058766-Cornelis1]. Two genetic risk scores were constructed in current study. The GRS*sel* included 8 SNPs which were associated with ANM (*P*\<0.05) in our study; the GRS*all* included all 22 SNPs evaluated. Relationships between GRS quartiles and ANM were evaluated by linear regression and ANOVA. All statistical analyses were conducted using SAS, version 9.2 (SAS Institute, Inc., Cary, N.C.).

Results {#s3}
=======

[Table 1](#pone-0058766-t001){ref-type="table"} presents the mean ANM by education, occupation, number of live births, use of oral contraceptives, age at menarche, and disease status. Significant differences of ANM were observed across each of these categories with the exception of age at menarche.

10.1371/journal.pone.0058766.t001

###### Characteristics of study participants.

![](pone.0058766.t001){#pone-0058766-t001-1}

  Variable                                 Category            N     *Age at natural menopause*                      
  ------------------------------- -------------------------- ------ ---------------------------- --------- --------- ---------
  Education                                                                                                 \<0.001  
                                             non              643              49.39               4.04              
                                          Elementary          725              49.42               3.84              
                                        Middle school         1000             49.12               3.49              
                                         High school          757              49.71               3.42              
                                   High profession/College+   407              50.48               3.32              
  Occupation                                                                                                \<0.001   \<0.001
                                         Professional         937              50.07               3.40              
                                           Clerical           642              49.61               3.52              
                                        Manual workers        1952             49.22               3.77              
  Number of live birth                                                                                      \<0.001  
                                              0               139              48.63               3.97              
                                              1               752              48.93               3.47              
                                              2               1261             49.90               3.35              
                                              3               772              49.66               4.09              
                                              4+              609              49.43               3.71              
  Ever take oral contraceptives                                                                   \<0.001            
                                              No              869              49.79               3.67              
                                             Yes              278              50.64               3.47              
  Age at menarche (years)                                                                          0.902    0.7179   
                                             ≤12              237              49.62               4.00              
                                              13              588              49.62               3.38              
                                              14              611              49.59               3.52              
                                              15              733              49.47               3.75              
                                              16              638              49.48               3.30              
                                              17              398              49.46               3.94              
                                             ≥18              326              49.32               4.21              
  Disease                                                                                         \<0.001   0.9861   
                                       Healthy controls       1308             49.20               3.77              
                                        Breast cancer         850              49.86               3.63              
                                      Endometrial cancer      427              50.42               3.41              
                                      Colorectal cancer       322              49.20               3.46              
                                       Upper GI cancer        160               49.0               3.76              
                                       Type 2 diabetes        466              49.31               3.46              

*P* for ANOVA.

*adjusting for Education.*

[Table 2](#pone-0058766-t002){ref-type="table"} shows the results of SNPs included in this study. 22 SNPs showed the same direction of association as previously reported (binomial sign test *P*\<1×10^−4^). Eight SNPs were nominally significant with *P*≤0.05: rs4246511 (*RHBDL2*), rs365132 (*UIMC1*), rs2307449 (*POLG*), rs1246111 (*NLRP11*), rs12611091 (*BRSK1*), rs1172822 (*BRSK1*), rs2720044 (*ASH2L*), and rs7246479 (*TMEM150B*). Notably, SNPs rs4246511 (*RHBDL2*), rs365132 (*UIMC1*), rs1172822 (*BRSK1*), and rs7246479 (*TMEM150B*) showed associations with P≤0.002 and remained significant even after Bonferroni correction. The per-allele effect on ANM was 0.287, 0.284, 0.600, 0.487 years for rs4246511, rs365132, rs1172822, and rs7246479. These estimates are comparable with previous results in European-ancestry women. No significant associations were found for the other 14 SNPs. Among them, three have a MAF\<0.05, including rs4886238, rs7123626, and rs7333181. Considering the disease of the subjects could also show overlap in the genetic architecture with menopausal age, the association analysis in the healthy controls was further performed as a sensitivity analysis and the results indicated that six SNPs of the above eight SNPs associated with ANM still showed association with P\<0.05 ([Table S2](#pone.0058766.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0058766.t002

###### Association results of 16 SNPs and age of natural menopause in Chinese women.
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  SNPs                                         Chr[d](#nt106){ref-type="table-fn"}   Position    Nearest gene   Allele   Reported studies   Shanghai population                                                                 
  ------------------------------------------- ------------------------------------- ----------- -------------- -------- ------------------ --------------------- -------------- ------- -------- ---------------------- ------- ---
  rs4246511                                                     1                    39152972      *RHBDL2*      C/T          0.187                0.240          1.02×10^−16^   0.612   0.287         **0.002**         0.879   Y
  rs1635501                                                     1                    240107398      *EXO1*       T/C          0.482               −0.164          8.46×10^−10^   0.235   −0.019          0.851           0.056  
  rs2303369                                                     2                    27568920      *FNDC4*       C/T          0.389               −0.175          8.40×10^−14^   0.139   −0.094          0.455           0.106  
  rs10183486                                                    2                    171699217      *TLK1*       C/T          0.357               −0.196          2.21×10^−14^   0.070   −0.166          0.325           0.165  
  rs4667673[a](#nt103){ref-type="table-fn"}                     2                    171551661      *TLK1*       C/G          0.375                                              0.386   0.144           0.121           0.353  
  rs4693089                                                     4                    84592646      *HEL308*      A/G          0.488                0.228          1.80×10^−19^   0.658   0.111           0.213           0.231  
  rs365132                                                      5                    176311180     *UIMC1*       G/T          0.491                0.39           2.60×10^−12^   0.504   0.284         **0.001**         0.869   Y
  rs1046089                                                     6                    31710946       *BAT2*       G/A          0.354               −0.213          1.45×10^−59^   0.336   −0.075          0.400           0.123  
  rs2153157                                                     6                    11005474      *SYCP2L*      G/A          0.491                0.165          7.76×10^−12^   0.677   0.166           0.075           0.412  
  rs2517388                                                     8                    38096889      *ASH2L*       T/G          0.178                0.262          2.47×10^−19^   0.662   0.071           0.445           0.123  
  rs2720044[b](#nt104){ref-type="table-fn"}                     8                    38099744      *ASH2L*       A/C          0.188                                              0.265   0.225         **0.029**         0.610   Y
  rs12294104                                                   11                    30339475      *MPPED2*      C/T          0.174                0.225          2.25×10^−12^   0.102   0.060           0.702           0.073  
  rs7123626[c](#nt105){ref-type="table-fn"}                    11                    30282441       *FSHB*       G/A          0.112                                              0.036   0.085           0.715           0.064  
  rs2277339                                                    12                    55432336      *PRIM1*       T/G          0.103               −0.380          3.56×10^−13^   0.274   −0.164          0.136           0.381  
  rs4886238                                                    13                    60011740      *TDRD3*       G/A          0.334                0.170          9.31×10^−15^   0.038   0.013           0.955           0.050  
  rs7333181                                                    13                    111019298      *SOX1*       G/A          0.120                0.520          2.38×10^−19^   0.038   −0.135          0.558           0.087  
  rs2307449                                                    15                    87664932       *POLG*       T/G          0.400               −0.184          9.53×10^−11^   0.341   −0.211        **0.019**         0.634   Y
  rs10852344                                                   16                    11924420     *COX6CP1*      T/C          0.482                0.168          1.01×10^−11^   0.847   0.188           0.130           0.356  
  rs12461110                                                   19                    61012475      *NLRP11*      G/A          0.326               −0.158          8.74×10^−10^   0.293   −0.201        **0.034**         0.558   Y
  rs12611091                                                   19                    60492141      *BRSK1*       T/C          0.480                0.330          1.10×10^−10^   0.773   0.285         **0.008**         0.767   Y
  rs1172822                                                    19                    60511657      *BRSK1*       C/T          0.390                −0.49          2.50×10^−8^    0.095   −0.600   **6.64×10** ^−**5**^   0.978   Y
  rs7246479                                                    19                    60516144     *TMEM150B*     G/T          0.480                0.360          2.90×10^−12^   0.815   0.487    **3.75×10** ^−**5**^   0.993   Y

In LD with GWAS-identified SNP rs10183486 in CEU (r^2^ = 0.863) but not in CHB (r^2^ = 0.005).

In LD with GWAS-identified SNP rs2517388 in CEU (r^2^ = 0.843) but not in CHB (r^2^ = 0.169).

In LD with GWAS-identified SNP rs12294104 in CEU (r^2^ = 0.877) but not in CHB (r^2^ = 0.070).

Chr: chromosome.

EAF: effect allele frequency.

Partial regression coefficient was calculated for years per allele change in ANM (years).

GRS: genetic risk score, Significant SNPs were selected in the calculation of the GRS*sel*.

GRS analyses also showed significant associations ([Table 3](#pone-0058766-t003){ref-type="table"}). A dose-response association was observed between the number of effect alleles and ANM. The average ANM across increasing quartiles of the GRS*sel* were 49.21, 49.34, 49.60 and 49.90 (*P* = 3.24×10^−9^). Similar association was observed for GRS*all* with women in the highest quartile starting menopause approximately 0.9 years later than those in the lowest quartile (*P* = 4.61×10^−11^).

10.1371/journal.pone.0058766.t003

###### Association analysis of GRS and ANM.
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  *GRSsel* quartile     N        ANM       *GRSall* quartile    N        ANM
  ------------------- ----- ------------- ------------------- ----- --------------
  Q1 (\<8.93)          892   49.21±3.78      Q1 (\<24.45)      881    49.00±3.72
  Q2 (8.93--9.96)      869   49.34±3.55    Q2 (24.45--26.45)   885    49.48±3.62
  Q3 (9.97--11.06)     888   49.60±3.61    Q3 (26.46--28.19)   877    49.69±3.41
  Q4 (≥11.07)          884   49.90±3.65       Q4 (≥28.20)      890    49.87±3.80
  *P* for trend              3.24×10^−9^     *P* for trend           4.61×10^−11^

Discussion {#s4}
==========

In this study, we evaluated 22 SNPs in GWAS-identified genetic loci for menopause age originally discovered in Europeans in our Chinese population. Significant associations were observed for 8 SNPs and association directions were all same as originally reported. Furthermore, six of eight SNPs were replicated to be correlated with ANM in the healthy controls. Of the 8 replicated SNPs, four were located in 19q13.42, including rs12461110 at exon 5 of *NLRP11*gene, rs7246479 at exon 8 of *TMEM150B* gene, rs1172822 and rs12611091 at introns 19 and 5, respectively, of the *BRSK1* gene. SNP rs12461110 results in a missense change from Proline to Leucine. The *NLRP11* gene was reported to be involved in multiprotein complexes called inflammasomes and implicated in the activation of proinflammatory caspases [@pone.0058766-Tschopp1]. SNP rs7246479 results in amino acid change from Leucine to Phenylalanine alanine. The *TMEM150B* gene encodes transmembrane protein 150B, which belongs to the DRAM/TMEM150 family and is involved in apoptosis pathway. SNP rs1172822 may affect the binding of the transcription factor CdxA and C/EBP binding sites (FASTSNP, <http://fastsnp.ibms.sinica.edu.tw>), whereas rs12611091 has no known or predicted function. *BRSK1* is highly expressed in the human brain and moderately expressed in mammalian ovaries [@pone.0058766-RodriguezAsiain1]. The *BRSK1* was previously published by multiple studies in European ancestry populations and was recently replicated in Hispanic women [@pone.0058766-Chen1]. Further functional exploration may shed insight to the role of the *BRSK1* gene or other genes impacting menopause.

SNP rs4246511 is located at intron 3 of the *RHBDL2* gene, which may function as an intramembrane serine protease [@pone.0058766-Lei1]. SNP rs2307449 is located at intron 18 of the *POLG* gene, which encodes the catalytic subunit of mitochondrial DNA polymerase. The enzyme is responsible for replication and repair of mitochondrial DNA, and modulates the balance between DNA synthesis and excision [@pone.0058766-Copeland1], [@pone.0058766-Foury1]. For the *ASH2L* gene, the previously reported SNP, rs2517388, did not replicate in our study. However, the other SNP rs2720044, which is in strong LD with rs2517388 in European-ancestry population with r^2^ = 0.843 but not in Asian-ancestry with r^2^ = 0.169, was significantly associated with ANM in our population. These results indicate that the *ASH2L* gene might harbor different susceptible variants to ANM across ethnic groups. The *ASH2L* is required during early embryogenesis [@pone.0058766-Stoller1] and recruited to the inactive X chromosome at the onset of stable X inactivation [@pone.0058766-Pullirsch1].

We did not replicate the association of other 14 SNPs with ANM. Similarly, in a recent study in Hispanic women, only two of 14 evaluated menopause loci were replicated [@pone.0058766-Chen1]. For the 14 non-replicated SNPs, we have limited statistical power (\<40%) to detect evidence of association. Allele frequency is different across ethnic groups, which may affect the confirmation. Among the 10 non-replicated SNPs, three showed very low MAF in our study. In addition, LD structure often differs across populations, and GWAS hits are typically markers in LD with functional alleles. Therefore, it is expected that many genetic variants identified in one population cannot be directly replicated in other populations. In addition, the effect size for the same SNP may differ across ethnic groups due to different environment exposure. This may also result in the non-replication of the SNPs in other ethnic groups. Furthermore, replication study with larger sample size would be warranted.

Strengths of the study include the focus on replicating significant GWAS-identified SNPs among Asian women and a relatively large sample size. Furthermore, we investigated SNPs in LD with the SNPs reported in European-ancestry but not in Asian-ancestry populations, which would enhance the genomic coverage of susceptible regions for ANM. Results observed in the present study should be interpreted considering several limitations. First, GWAS-identified SNPs were selected only if they met a GWAS significance threshold (*P*\<5×10^−8^), and some SNPs with less significant *P*-values may be ignored. Second, different studies used different genotyping platforms, and there are only a small portion of SNPs overlapping between these platforms. Some SNPs were directly genotyped in some parent studies but imputed in other parent studies. Third, no surrogate SNP was identified for rs16991615 and rs236114, and we did not investigate these two loci. Fourth, ANM was self-reported with measured error, although this error is unlikely to be associated with genotype.

In summary, we successfully replicated eight SNPs associated with age at natural menopause in Chinese women. This is the first report of the common shared genetic architecture affecting menopause between European and Chinese women. Further research on these genetic regions will enhance our understanding of the genetic determination of menopause.
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